Ontozry

News

Angelini rapped for criticism of EMA approval

Angelini has been rapped under the UK pharma industry's code of practice for criticising licensing decisions made by the EMA and other breaches.

News

Illustration of a nerve cell on a colored background with light effects

Drug-resistant epilepsy drug Ontozry backed by NICE

NHS patients in England and Wales with drug-resistant epilepsy are in line for access to another treatment option, after NICE recommended routine use of Angelini group company Arvelle Pharm

Oncology

LSX2026: Addressing adult eye cancer, with Roi Raz

Roi Raz, CEO of ReBio Pharma, discusses injectable, bioresorbable sustained release delivery for ophthalmic therapeutics at LSX 2026.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Sales & Marketing

Using AI-driven synthetic personas to take your insights fur...

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.

Editor's Picks